香蕉网视频,成人精品自拍,狠狠色噜噜狠狠狠狠色综合网

Global Biopharma Layoffs November 2025 Layoffs Layoff Novatis AbbVie Bayer Merck This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs October 2025 Layoffs Layoff Novo Nordisk Takeda GSK This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs September 2025 Layoffs Layoff Novartis Merck Novo Nordisk The biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
Hansoh Pharma H1 2025 Financial Report Hansoh Pharma Chinese Pharmaceutical Market Financial statements Hansoh Pharma’s 2025 interim report highlights strong growth, innovation-driven transformation, and a robust global pipeline, setting a new benchmark for Chinese biopharma.
Rongchang Biopharma H1 2025 Financial Report Rongchang Biopharma Chinese Pharmaceutical Market Financial statements Rongchang Biopharma’s 2025 interim report shows 48% revenue growth, rising margins, reduced losses, and accelerated global BD deals, highlighting strong R&D, commercialization, and international expansion momentum.
Novartis' Triple Phase III Study Success: Dual-Action Anti-BAFF-R Monoclonal Antibody Triumph Novartis Autoimmune Autoimmune Drug Novartis' anti-BAFF-R antibody Ianalumab achieves breakthrough results in three Phase III trials for Sj?gren’s syndrome and immune thrombocytopenia, paving way for new autoimmune therapies.
Bayer $1.3 Billion Collaboration Agreement Bayer Kumquat Biosciences Bayer and Kumquat Biosciences announce a $1.3 billion global collaboration to develop and commercialize a KRAS G12D inhibitor, aiming to offer new treatment options for pancreatic, colorectal, and lung cancer patients.
First Global DPP1 Inhibitor Approved by FDA FDA Insmed The FDA has approved brensocatib, the world’s first DPP1 inhibitor, for treating non-cystic fibrosis bronchiectasis in patients aged 12+, marking a breakthrough in targeted respiratory therapies.
Gilead Q2 2025 Financial Report Financial statements Gilead Gilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
Global Biopharma Layoffs August 2025 Layoffs Layoff Merck Moderna Bayer Pfizer The biopharmaceutical industry sees major August layoffs, with companies like Moderna, Merck cutting jobs amid restructurings, trial setbacks, and M&A activity.